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Primitive neuroectodermal tumours (PNET) are the most frequent
primary malignant childhood brain tumours (Farwell et al, 1977;
Bigner et al, 1988). Medulloblastomas represent the majority of
cerebral PNET and are located in the cerebellum. Because of diffi-
culties in generating adequate metaphases, cytogenetic data in
these tumour types are still limited. The most frequent abnormality
is isochromosome i(17q), found in approximately 30% of cases
analysed with conventional cytogenetics (Bigner et al, 1988;
Griffin et al, 1988; Biegel et al, 1989; Karnes et al, 1992; Vagner-
Capodano et al, 1992; Neumann et al, 1993; Fujii et al, 1994). This
high incidence of i(17q) was confirmed in a molecular cytogenetic
study, which also showed deletions of 17p in 44% of patients
(Biegel et al, 1995). Other studies using molecular approaches
confirmed this frequent loss of 17p, and localized a hot-spot of
loss of heterozygosity at 17p13.3, a locus telomeric to the p53
gene (Biegel et al, 1992; Cogen et al, 1992; McDonald et al, 1994;
Batra et al, 1995). A very recent deletion mapping study localized
a common chromosomal disruption within a more centromeric
region, at 17p11.2 (Scheurlen et al, 1997). Other recurrent abnor-
malities have been described, including structural aberrations of
chromosomes 1, 3, 6, 11, 16 and X, loss of chromosome 22 and
gains of chromosomes 6 and 8 (Farwell et al, 1977; Bigner et al,
1988, 1990; Griffin et al, 1988; Callen et al, 1989; Karnes et al,
1992; Neumann et al, 1993; Fujii et al, 1994). Few gene amplifica-
tions have been reported, involving MYC, MYCN or EGFR (Rouah
et al, 1989; Wasson et al, 1990; Fuller and Bigner, 1992; Badiali et
al, 1995), and more recently the 5p15 and 11q22 chromosomal
regions (Reardon et al, 1997).
The recently developed technique of comparative genomic
hybridization (CGH) allows a genome-wide screening for
unbalanced abnormalities, without the requirement for tumour
metaphases (reviewed in Kallioniemi et al, 1994). Only two
studies using this approach in PNET have previously been
reported (Schutz et al, 1996; Reardon et al, 1997). In order to
extend our knowledge on recurrent imbalances in this disease, we
analysed frozen tumour samples obtained from 23 children with
either medulloblastoma (21 patients) or supratentorial PNET (two
patients). We found many recurrent abnormalities, especially gains
of 17q, 1q and 7, and losses of chromosomes 3, 8, 10q, 11, 21
and X.
MATERIALS AND METHODS
Patients
Primary brain tumour tissue samples were obtained from 23
patients with a PNET. Samples were obtained at diagnosis in 22
patients and at time of relapse in 1 patient, a 13-year-old boy with
a non-metastatic medulloblastoma (patient 221) (Table 1). There
were 11 girls and 12 boys with a median age of 7.5 years (range 9
months–13 years). Twenty-one patients had a cerebellar tumour,
i.e. medulloblastoma, and two a supratentorial PNET. The disease
was metastatic at diagnosis in nine patients with newly diagnosed
medulloblastoma, as assessed by magnetic resurance imaging
(MRI) and cerebrospinal fluid (CSF) analysis. Tissue samples
were immediately frozen in liquid nitrogen upon tumour removal
and stored at –80°C until analysis. For histological analysis, tissue
Comparative genomic hybridization detects many
recurrent imbalances in central nervous system
primitive neuroectodermal tumours in children
H Avet-Loiseau1, A-M Vénuat2, M-J Terrier-Lacombe3, A Lellouch-Tubiana5, M Zerah6 and G Vassal4
1Laboratory of Hematology, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cédex 1, France; 2Laboratory of Genetics and Cytogenetics, 3Department of
Pathology, 4Department of Pediatric Oncology and CNRS URA 147, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cédex, France;
5Department of Pathology, 6Department of Pediatric Neurosurgery, Hopital Necker-Enfants Malades, 149 rue de Sevres, 75743 Paris Cedex 15, France
Summary A series of 23 children with primitive neuroectodermal tumours (PNET) were analysed with comparative genomic hybridization
(CGH). Multiple chromosomal imbalances have been detected in 20 patients. The most frequently involved chromosome was chromosome
17, with a gain of 17q (11 cases) and loss of 17p (eight cases). Further recurrent copy number changes were detected. Extra copies of
chromosome 7 were present in nine patients and gains of 1q were detected in six patients. A moderate genomic amplification was detected
in one patient, involving two sites on 3p and the whole 12p. Losses were more frequent, and especially involved the chromosomes 11 (nine
cases), 10q (eight cases), 8 (six cases), X (six patients) and 3 (five cases), and part of chromosome 9 (five cases). These recurrent
chromosomal changes may highlight locations of novel genes with an important role in the development and/or progression of PNET.
Keywords: CGH; PNET; medulloblastoma; FISH; cytogenetics
1843
British Journal of Cancer (1999) 79(11/12), 1843–1847
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0293
Received 19 May 1998
Revised 25 August 1998
Accepted 18 September 1998
Correspondence to: H Avet-Loiseau, Laboratory of Hematology, Biology
Institute, 9 quai Moncousu, 44093 Nantes Cedex, Francespecimens were fixed in acetic acid–formalin–ethanol (AFA;
Carlo-Erba, Milan, Italy) and embedded in paraffin. Paraffin-
embedded sections were then routinely stained with haema-
toxylin–eosin–saphranin (HES). Appropriate immunohistochemical
analysis was performed when needed to rule out a differential diag-
nosis, especially for supratentorial tumours.
Comparative genomic hybridization
CGH was performed as previously described (Paszek-Vigier et al,
1997). Briefly, tumour DNA was extracted using phenol–chloro-
form technique. Tumour DNA was labelled by nick translation
with Texas red (TR)-dUTP (Dupont-NEN), whereas normal DNA
from heathy male and female donors was labelled with fluorescein
isothiocyanate (FITC)-dUTP (Dupont-NEN). A total of 150 ng of
each donor’s DNA and 20 mg of unlabelled Cot-1 DNA (Gibco,
BRL) were ethanol precipitated, resuspended in Hybrisol VII
(Oncor, Gaithersburg, MD, USA) and denatured for 10 min. After
a 48-hour hybridization at 37°C, slides were washed for 5 min in
2 ´ saline–sodium citrate (SSC) at 73°C and examined using an
epifluorescence microscope (DMRB, Leica). CGH analysis was
performed using Powergene software (PSI, Houston, TX, USA).
The over- and under-represented DNA segments were determined
by calculating TR:FITC average ratio profiles. Average ratio
images were calculated from at least six metaphases and had fixed
thresholds. Chromosomal gains were considered when fluores-
cence ratios exceeded 1.15 and losses were considered for ratios
lower than 0.85. Telomeric and heterochromatic regions were
excluded from analysis, according to Kallioniemi et al (1994), as
well as chromosomes 1p, 16q, 19, 22 and Y. Genomic amplifica-
tion was defined by a red/green ratio > 1.5.
RESULTS
CGH analysis was successfully performed for the 23 tested
patients. Figure 1 summarizes the copy number changes detected
in the 23 patients. Twenty contained aberrations in at least one
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Table 1 Main clinical characteristics and CGH results of the 23 patients
Patient Sex Age Histology Tumour location Metastasis CGH results
no. (years) Gains Losses
89 F 3 Medulloblastoma Posterior fossa No 6, 8, 13, 17q 4q, 10, 11, 21, X
99 F 4 PNET with glial Supratentorial No 1q, 2, 17
component
107 M 9 Medulloblastoma Posterior fossa No 7, 17q 2q14q33, 3, 11, 17p
127 M 9.7 Medulloblastoma Posterior fossa No 1q, 2, 12q22qter, 17q 3, 8, 10, 11, 17p
161 M 4.1 Medulloblastoma Posterior fossa No 5, 7, 17q 3, 8, 11, 15, 17p, 20
202 M 12.2 Medulloblastoma Posterior fossa No 7 2, 3, 8, 9pterq22, 13, 15, 20
208 M 4.2 PNET with glial Supratentorial No 9pterq22, 11q23qter
component
221 M 13 Medulloblastoma Posterior fossa * 7, X 8p, 10q, 11, 13
222 M 6.4 Medulloblastoma Posterior fossa No 3pterp24, 3p23p21, 12p 17p
223 F 12.7 Medulloblastoma Posterior fossa No 6
228 M 8.9 Medulloblastoma Posterior fossa No 1q, 7, 17q 9p21q21
234 M 12 Medulloblastoma Posterior fossa No 1p31qter, 4, 5, 7, 18 8, 9, 10, 11, 12p12q14, 16, 21
245 F 7.5 Medulloblastoma Posterior fossa No 1q31qter, 3q, 13, Xq 3p, 10q, 14q21qter
249 F 7.7 Medulloblastoma Posterior fossa No 4, 7, 17 8, 10, 11, 15q11q15, X
77 F 6.6 Medulloblastoma Posterior fossa Yes 7, 12pterq12, 15q25qter, 17q 3, 13, 17p, X
81 F 6.9 Medulloblastoma Posterior fossa Yes 1q, 5, 6, 8q 7p, 21, X
84 F 2.2 Medulloblastoma Posterior fossa Yes 7, 10p, 13, 14, 17 4, 8, 10q, 11, 15, 21, X
113 M 1.4 Medulloblastoma Posterior fossa Yes 2, 6q10q24 16p, 17pterq23
164 F 11 Medulloblastoma Posterior fossa Yes Normal
207 F 1.2 Medulloblastoma Posterior fossa Yes Normal
212 F 3.9 Medulloblastoma Posterior fossa Yes 1031qter, 7q, 13q31qter, 17q 10q, 17p, X
214 M 0.7 Medulloblastoma Posterior fossa Yes Normal
227 M 9.5 Medulloblastoma Posterior fossa Yes 4q22qter, 17q 9p13q21, 17p, 20
aTumour sample was obtained at time of relapse. M, male; F, female.CGH in childhood PNET 1845
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Figure 1 Summary of the chromosomal gains and losses found in this series. Vertical lines on the right side of a chromosome represent a gain of genetic
material and a vertical line on the left side a loss of material. Thick lines show genomic amplificationschromosomal region. The number of imbalances ranged from 0 to
13 (median = 6). The most frequent abnormality was a gain of 17q
in 11 cases. Other recurrent abnormalities were a gain of chromo-
some 7 (nine patients), loss of 11 (eight patients), loss of 17p
(eight patients), loss of 10q (eight patients), loss of chromosome X
(six patients), loss of 8 (six patients), gain of 1q (six patients) and
loss of chromosomes 3 and 9p (five patients each). The coexis-
tence of gain of 17q and loss of 17p in six patients was suggestive
of an isochromosome i(17q). Multiple copy numbers involving 3p
and 12p were found in one patient (Figure 2). No amplification
was found at other classical amplified loci (MYC, MYCN or
EGFR). In the analyses, we also separated metastatic patients from
children with localized disease. Among recurrent abnormalities
described above, loss of chromosome 11 appeared to be less
frequent in children with metastatic PNET.
DISCUSSION
CGH has been used for the identification of chromosomal imbal-
ances in a wide variety of solid tumours and haematologic malig-
nancies. This technique circumvents many limitations associated
with conventional cytogenetics, such as the difficulty to obtain
metaphases in tumour cells or the often poor quality of chromo-
some spreads associated with the frequent high-complexity of
chromosomal changes. Moreover, CGH does not require fresh
tumour material, and even small pieces of tumour can be analysed.
For all these reasons, CGH is a very powerful technique for the
analysis of chromosomal changes in solid tumours. However,
some limitations exist. Balanced chromosomal rearrangements are
not detected and some regions, including 1p, 16q, 19, 22 and Y, are
difficult to analyse. In this study, we detected chromosomal imbal-
ances in 20 out of 23 tumours analysed. No abnormality was
detected in three patients with metastatic disease, corresponding
either to patients with a normal karyotype or only balanced struc-
tural abnormalities, or to patients with an important contamination
with normal cells. Losses were slightly more frequent than gains
(75 versus 60), and many recurrent chromosomal changes were
found.
In agreement with published cytogenetic data, chromosome 17
was the most frequently involved. Gain of 17q was found in 11
patients (half of the abnormal patients) and loss of 17p was found
in eight patients. In six cases, both abnormalities were present
simultaneously, indicating the probable presence of an i(17q).
Nevertheless, some patients have only gain of 17q and others have
only loss of 17p, suggesting that these two abnormalities may
involve different tumorigenic pathways. Recent data showed that
different regions may be lost in 17p deletions, leading to the loss
of different putative tumour suppressor genes (Biegel et al, 1992;
Cogen et al, 1992; McDonald et al, 1994; Batra et al, 1995;
Scheurlen et al, 1997). On the other hand, gain of chromosome
17q (through the formation of an isochromosome or an isolated
gain of 17q) is probably an important second event, by modifying
some gene dosage. This phenomenon has to be related to abnor-
malities described in another neuroectodermal tumour, i.e. neuro-
blastoma. Recently, it has been shown that gains of 17qter material
were present in about 90% of high-grade neuroblastomas (Meddeb
et al, 1996). Because neuroblastomas and medulloblastomas are
both neuroectodermal tumours, a common tumorigenic event may
be proposed, even if no candidate gene has so far been found.
We also found many other abnormalities, especially extra copies
of chromosome 7 and losses of chromosomes 11 and 10q. Most of
them are in agreement with data reported by Reardon et al (1997),
but strongly differ from Schutz et al’s data (1996). Both trisomy 7
and loss of chromosome 10 are the hallmark of another type of
brain tumour, glioblastoma multiforme (Bigner et al, 1990). This
tumour is especially frequent in adults, but rather rare in child-
hood. Moreover, embryologic origins of glioblastomas and medul-
loblastomas are totally different. The former is a glial tumour,
whereas medulloblastoma is a neuroectodermal tumour. Are there
common genetic abnormalities in childhood brain malignancies?
This question has to be raised, but larger series will be needed to
address this question.
Loss of 11q has already been reported in medulloblastomas
(Callen et al, 1989; Vagner-Capodano et al, 1992; Reardon et al,
1997). Vagner-Capodano et al (1992) suggested that tumours with
11q abnormalities might constitute a subgroup of medulloblas-
toma different from tumours with an i(17q). Our results do not
support this hypothesis. In our series, six patients had abnormali-
ties of both chromosome 11 and 17; three with monosomy 11 and
an i(17q) and three with monosomy 11 and gain of chromosome
17 or 17q. The loss of chromosome 11 was found to be more
frequent in patients with localized disease (8/14 versus 1/9). Even
if these respective frequencies are statistically different, a larger
series would be necessary to conclude.
Other recurrent abnormalities were loss of chromosome X, 3, 8
and 9p–9q21–22, and gain of chromosome 1q. This latter abnor-
mality is not a medulloblastoma-specific change since it has been
described in a large variety of tumour types. Loss of chromosome
9p has been reported in adult gliomas, but not in childhood medul-
loblastoma. In adults, it seems to lead to p15/p16 deletions (Jen et
al, 1994; Barker et al, 1997). Interestingly, the five patients with a
chromosome 9 deletion share a loss of the q21–22 region.
Recently, mutations of the PTCH gene, which maps at 9q22, have
been reported in medulloblastoma (Pietsch et al, 1997; Wolter et
al, 1997). We can speculate that these deletions in our patients
include this gene. Losses in chromosome 3 have not been reported
as non-random changes in medulloblastomas. We found loss of
chromosome 3 in five patients, plus one patient with loss of 3p and
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Figure 2 A partial CGH ‘karyotype’ showing low-level amplifications on
chromosomes 3 (averaged profile from eight copies of chromosome 3) and
12 (averaged profile from ten copies of chromosome 12) (patient 222). The
median thick line represents the ratio 1, the left line the ratio 0.5 and the right
line the ratio 1.5. This patient displays two different amplified regions on the
short arm of chromosome 3 and multiple copy numbers of the short arm of
chromosome 12gain of 3q (suggesting the presence of an isochromosome 3q). The
entire chromosome 8 was lost in six patients and another patient
exhibited loss of chromosome 8p. These losses of chromosome 8
material are in agreement with Reardon et al’s data (1997), which
found a recurrent loss of the short arm of chromosome 8. Many
genes localized on 3p or 8p could potentially be the main target of
these deletions, and more patients will be necessary to try to define
the critical minimal deleted region.
No high-level amplification has been found in this study. Only
one patient displayed multiple copy number changes: two gains on
3p (3p21 and 3p25) and one gain of the entire chromosome 12
short arm. In these three cases, deviations from the baseline are
compatible with multiple copy numbers. These regions have not
been previously reported. Amplifications have rarely been
reported in medulloblastomas, usually as double minutes. When
analysed, the target genes of these amplifications were either
MYC, MYCN or EGFR (Rouah et al, 1989; Wasson et al, 1990;
Fuller and Bigner, 1992), and more recently the 5p15 and 11q22
regions (Reardon et al, 1997). None of these regions was amplified
in our series.
In conclusion, this CGH study identified many non-random
copy number changes, confirming data from the Reardon group
(1997). Larger series of consecutive patients would define the
exact frequency and significance of these individual chromosomal
abnormalities. This analysis prompts the elaboration of large
prospective studies in order to determine the potential prognostic
significance of these copy number changes.
ACKNOWLEDGEMENTS
We thank Professor Alain Pierre-Kahn, Professor Christian Sainte-
Rose and all the staff of the Department of Pediatric Neurosurgery
operating theater (Hopital Necker) for their help in providing us
with brain tumour tissue samples. This study was supported by the
Comite de Loire-Atlantique de la Ligue contre le Cancer.
REFERENCES
Badiali M, Pession A, Basso G, Andreini L, Rigobello L, Galassi E and Giangaspero
F (1995) N-myc and c-myc oncogenes amplification in medulloblastoma:
evidence of particularly aggressive behaviour of a tumor with c-myc
amplification. Tumori 77: 118–121
Barker FG, Chen P, Furman F, Aldape KD, Edwards MS and Israel MA (1997) P16
deletion and mutation analysis in human brain tumors. J Neurdoncol 31: 17–23
Batra S, McLendon R, Koo JS, Castelino-Prabhu S, Fuchs H, Krischer J, Friedman
H, Bigner D and Bigner H (1995) Prognostic implications of chromosome 17p
deletions in human medulloblastomas. J Neurooncol 24: 39–45
Biegel JA, Rorke LB, Packer RJ, Sutton LN, Schut L, Bonner K and Emanuel BS
(1989) Isochromosome 17q in primitive neuroectodermal tumors of the central
nervous system. Genes Chromosomes Cancer 1: 139–147
Biegel JA, Burk CD, Barr FG and Emanuel BS (1992) Evidence for a 17p tumor-
related locus distinct from p53 in pediatric primitive neuroectodermal tumors.
Cancer Res 52: 2347–2350
Biegel JA, Rorke LB, Janss AJ, Sutton LN and Parmiter AH (1995) Isochromosome
17q demonstrated by interphase fluorescence in situ hybridization in primitive
neuroectodermal tumors of the central nervous system. Genes Chromosomes
Cancer 14: 85–96
Bigner SH, Mark J, Friedman HS, Biegel JA and Bigner DD (1988) Structural
chromosomal abnormalities in human medulloblastoma. Cancer Genet
Cytogenet 30: 91–101
Bigner SH, Mark J and Bigner DD (1990) Cytogenetics of human brain tumors.
Cancer Genet Cytogenet 47: 141–154
Callen DF, Cirocco L and Moore L (1989) A der(11)t(8;11) in two
medulloblastomas: a possible non-random cytogenetic abnormality. Cancer
Genet Cytogenet 38: 255–260
Cogen PH, Daneshvar L, Metzger AK, Duyk G, Edwards MS and Sheffield VC
(1992) Involvement of multiple 17p loci in medulloblastoma tumorigenesis.
Am J Hum Genet 50: 584–589
Farwell JR, Dohrmann GJ and Flanner JT (1977) Central nervous system tumors in
children. Cancer 40: 3123–3132
Fujii Y, Hongo T and Hayashi Y (1994) Chromosome analysis of brain tumors in
childhood. Genes Chromosomes Cancer 11: 205–215
Fuller GN and Bigner SH (1992) Amplified cellular oncogenes in neoplasms of the
human nervous system. Mutat Res 276: 299–306
Griffin CA, Hawkins AL, Packer FJ, Rorke LB and Emanuel BS (1988)
Chromosome abnormalities in pediatric brain tumors. Cancer Res 48: 175–180
Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson
JK, Kinzler KW and Vogelstein B (1994) Deletion of p16 and p15 genes in
brain tumors. Cancer Res 54: 6353–6358
Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW and Pinkel
D (1994) Optimizing comparative genomic hybridization for analysis of DNA
sequence copy number changes in solid tumors. Genes Chromosomes Cancer
10: 231–243
Karnes PS, Tuan NT, Cui MY, Raffel C, Gilles FH, Barranger JA and Ying KL
(1992) Cytogenetic analysis of 39 pediatric central nervous system tumors.
Cancer Genet Cytogenet 59: 12–19
McDonald J, Daneshvar L, Willert J, Matsumara K, Waldman F and Cogen P (1994)
Physical mapping of chromosome 17p 13.3 in the region of a putative tumor
suppressor gene important in medulloblastoma. Genomics 23: 229–232
Meddeb M, Danglot G, Chudoba I, Venuat AM, Bénard J, Avet-Loiseau H, Vasseur
B, Le Paslier D, Terrier-Lacombe MJ, Hartmann O and Bernheim A (1996)
Additional copies of a 25 Mb chromosomal region originating from
17q23. 1-qter are present in 90% of high-grade neuroblastomas. Genes
Chromosomes Cancer 17: 156–165
Neumann E, Kalousek D, Norman M, Steinbok P, Cochrane D and Goddard K
(1993) Cytogenetic analysis of 109 pediatric central nervous system tumors.
Cancer Genet Cytogenet 71: 40–49
Paszek-Vigier M, Talmant P, Méchinaud F, Garand R, Harousseau JL, Bataille R and
Avet-Loiseau H (1997) Comparative genomic hybridization is a powerful tool,
complementary to cytogenetics, to identify chromosomal abnormalities in
childhood acute lymphoblastic leukemia. Br J Haematol 99: 589–596
Pietsch T, Waha A, Koch A, Kraus J, Albrecht S, Tonn J, Sorensen N, Berthold F,
Henk B, Schmandt N, Wolf HK, von Deimling A, Wainwright B, Chenevix-
Trench G, Wiestler OD and Wicking C (1997) Medulloblastomas of the
desmoplastic variant carry mutations of the human homologue of Drosophila
patched. Cancer Res 57: 2085–2088
Reardon DA, Michalkiewicz E, Boyett JM, Sublett JE, Entrekin RE, Ragsdale ST,
Valentine MB, Behm FG, Li H, Heideman RL, Kun LE, Shapiro DN and Look
AT (1997) Extensive genomic abnormalities in childhood medulloblastoma by
comparative genomic hybridization. Cancer Res 57: 4042–4047
Rouah E, Wilson DR, Armstrong DL and Darlington GJ (1989) N-myc amplification
and neuronal differentiation in human primitive neuroectodermal tumors of the
central nervous system. Cancer Res 49: 1797–1801
Scheurlen WG, Seranski P, Mincheva A, Kuhl J, Sorensen N, Krauss J, Lichter P,
Poustka A and Wilgenbus KK (1997) High-resolution mapping of chromosome
arm 17p in childhood primitive neuroectodermal tumors reveals a common
chromosomal disruption within the the Smith-Magenis region, an unstable
region in chromosome band 17p11.2. Genes Chromosomes Cancer 18: 50–58
Schutz BR, Scheurlen W, Krauss J, Du Manoir S, Joos S, Bentz M and Lichter P
(1996) Mapping of chromosomal gains and losses in primitive neuroectodermal
tumors by comparative genomic hybridization. Genes Chromosomes Cancer
16: 196–203
Vagner-Capodano AM, Gentet JC, Gambarelli D, Pellissier JF, Gouzien M, Lena G,
Genitori L, Choux M and Raybaud C (1992) Cytogenetic studies in 45 pediatric
brain tumors. Pediatr Hematol Oncol 9: 223–235
Wasson JC, Saylors III LS, Zeltzer P, Friedman HS, Bigner SH, Burger PC, Bigner
DD, Look AT, Douglass EC and Brodeur GM (1990) Oncogene amplification
in pediatric brain tumors. Cancer Res 50: 2987–2990
Wolter M, Reifenberger J, Sommer C, Ruzicka T and Reifenberger G (1997)
Mutations in the human homologue of the Drosophila segment polarity gene
patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive
neuroectodermal tumors of the central nervous system. Cancer Res 57:
2581–2585
CGH in childhood PNET 1847
British Journal of Cancer (1999) 79(11/12), 1843–1847 © Cancer Research Campaign 1999